Liraglutide (Victoza) for weight loss: what the evidence says
Quick answer
This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.8 mg daily. The higher-dose formulation, Saxenda (3.0 mg), holds the FDA approval for chronic weight management, and conflating these two indications in patient-facing content can create unrealistic expectations or inappropriate off-label use. Because the audio transcript is largely unintelligible, likely due to Spanish-to-English auto-caption failure, no specific medical claims can be directly verified from this video's spoken content.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @anais_dena actually say?
Honestly? It is hard to tell. The transcript for this video is largely incoherent, likely the result of auto-generated captions failing to accurately capture Spanish-language audio. What we can piece together from context, the hashtags, and visual cues is that this creator documented a personal weight loss experience using liraglutide (brand name Victoza), a GLP-1 receptor agonist. The caption uses hashtags like #victozaweightloss, #liraglutida, and #perdidadepeso (weight loss in Spanish), and frames this as a personal transformation journey. There is no clear verbal claim about dosage, mechanism, or medical outcomes that we can directly quote and verify. What we have is a before-and-after story shared with nearly 94,000 viewers, many of whom may be considering GLP-1 medications themselves.
Does the science back this up?
The general premise, that liraglutide can support meaningful weight loss, is well-supported by clinical evidence. Whether Victoza specifically is the right tool for weight loss is a more complicated conversation.
Liraglutide is FDA-approved for two distinct purposes. Victoza (1.2 mg or 1.8 mg daily) is approved for type 2 diabetes management. Saxenda (up to 3.0 mg daily) is the higher-dose version approved specifically for chronic weight management. The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that adults without diabetes taking 3.0 mg liraglutide lost an average of 8.4 kg over 56 weeks, compared to 2.8 kg on placebo. That is a real effect, but it is dose-dependent. Using Victoza off-label for weight loss, at diabetes doses, may produce less pronounced results than Saxenda.
GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity. These are legitimate, studied mechanisms, not wellness industry hand-waving.
What did they get wrong (or right)?
Because the transcript is essentially unusable for factual extraction, we cannot attribute specific errors to the creator's spoken words. That is not a pass, though. It is a problem.
What this video does implicitly, through its hashtag framing, is position Victoza as a weight loss drug. That is only partly accurate. Victoza is a diabetes drug that can produce weight loss as a secondary benefit. Saxenda is the weight loss drug. Conflating the two in a 94,000-view video, without that distinction, could lead viewers to seek a diabetes medication when a weight-management-specific approval exists, or to expect Saxenda-level results from a Victoza dose.
On the positive side, personal documentation of GLP-1 experiences, when done responsibly, helps reduce stigma around medical weight management. There is real value in patients sharing that these medications involve an ongoing process, not a one-time fix. The creator's framing of this as a journey rather than an overnight transformation is, at minimum, not misleading in tone.
What should you actually know?
If you are watching this video and wondering whether liraglutide is right for you, here is what the evidence actually says.
- Liraglutide requires a prescription and medical supervision. It is not a supplement or a shortcut.
- Victoza and Saxenda contain the same active ingredient at different approved doses for different indications. They are not interchangeable without a prescriber's guidance.
- Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation. The SCALE trial reported that roughly 40% of participants experienced nausea.
- Weight loss with liraglutide typically requires sustained use. Davies et al. (2015, Lancet Diabetes and Endocrinology) found that stopping the medication results in weight regain in most patients.
- Liraglutide carries an FDA boxed warning about a potential risk of thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
Seeing a transformation video on TikTok is not a substitute for a clinical evaluation. If you are curious about GLP-1 therapy, that conversation belongs with a licensed provider who knows your full medical history.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Liraglutide (Victoza) for weight loss: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Liraglutide (Victoza) for weight loss: what the evidence says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.
FormBlends verdict
This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.8 mg daily. The higher-dose formulation, Saxenda (3.0 mg), holds the FDA approval for chronic weight management, and conflating these two indications in patient-facing content can create unrealistic expectations or inappropriate off-label use. Because the audio transcript is largely unintelligible, likely due to Spanish-to-English auto-caption failure, no specific medical claims can be directly verified from this video's spoken content.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video documents a personal weight loss experience with liraglutide (Victoza), a GLP-1 receptor agonist FDA-approved for type 2 diabetes at doses up to 1.8 mg daily. The higher-dose formulation, Saxenda (3.0 mg), holds the FDA approval for chronic weight management, and conflating these two indications in patient-facing content can create unrealistic expectations or inappropriate off-label use. Because the audio transcript is largely unintelligible, likely due to Spanish-to-English auto-caption failure, no specific medical claims can be directly verified from this video's spoken content.
- Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the weight management approval. They are not the same product for regulatory or clinical purposes.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found 3.0 mg liraglutide produced 8.4 kg average weight loss over 56 weeks vs. 2.8 kg on placebo in non-diabetic adults.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the weight management approval. They are not the same product for regulatory or clinical purposes.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found 3.0 mg liraglutide produced 8.4 kg average weight loss over 56 weeks vs. 2.8 kg on placebo in non-diabetic adults.
- Weight regain is common after stopping liraglutide. Davies et al. (2015, Lancet Diabetes and Endocrinology) found most patients regain weight within months of discontinuation.
- Liraglutide carries an FDA boxed warning for potential thyroid C-cell tumor risk observed in rodents, and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
- Approximately 40% of participants in the SCALE trial reported nausea, making it the most common side effect, typically peaking during dose escalation phases.
- The video transcript is largely incoherent, most likely due to auto-captioning failure on Spanish-language audio, meaning no specific spoken medical claims can be verified or fact-checked directly.
- Compounded liraglutide products are not FDA-approved and cannot be assumed equivalent to brand-name Victoza or Saxenda in potency, sterility standards, or clinical validation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Anaís Dena · TikTok creator
93.7K views on this video
Mi proceso con #victoza #weightloss #liraglutida #weightlosstransformation #victozaweightloss #inyeccion #perdidadepeso #diabetes #obesidad #fy #amorpropio #loveyourself #fyp #foryoupage #paratii
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Anaís Dena, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.